Lucie M. Kappelle-Hijmering

Groningen, GR 9713GZ, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Prevalence and characteristics of persistent taste and smell dysfunction after immune checkpoint inhibitor therapy for cancer.

Prevalence and characteristics of persistent taste and smell dysfunction after immune checkpoint inhibitor therapy for cancer.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: December 17, 2025

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases.

Clinical risk factors for developing brain metastases during first-line (chemo-)immunotherapy in patients with non-small cell lung cancer without known baseline brain metastases.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 28, 2025

Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy.

Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy.

Journal: Acta oncologica (Stockholm, Sweden)

Published: November 04, 2024

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer.

Journal: Cancers

Published: June 21, 2024

The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study.

The additional diagnostic value of virtual bronchoscopy navigation in patients with pulmonary nodules - The NAVIGATOR study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: November 14, 2022

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 21, 2022

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.

Actionability of on-target ALK Resistance Mutations in Patients With Non-Small Cell Lung Cancer: Local Experience and Review of the Literature.

Journal: Clinical lung cancer

Published: April 30, 2021

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles.

Journal: JCO precision oncology

Published: November 01, 2020

Showing 1-8 of 8

Last Updated: 09/26/2026